Proteins are made up of long chains of amino acids. Proteins play a pivotal role in the regulation of all biological functions including DNA replication and metabolic reactions in the body. Bio-engineered proteins are developed by using genetic engineering. Bio-engineered proteins are used to treat human injury and provide effective treatments to prevent from life-threatening diseases.
The global bioengineered protein drugs market is categorized into monoclonal antibodies, cytokines, peptide hormones, vaccines, therapeutic enzymes and blood products. The cytokines segment includes interferon, interleukins and colony stimulating factors. The peptide hormone segment is sub-divided into insulin, growth hormones and erythropoietin. Vaccines include toxoid, live attenuated vaccines and killed vaccines. The therapeutic enzyme segment is further sub-segmented into digestive and metabolic enzymes. Blood products include thrombin, alpha 1-Protease inhibitor and coagulation factors.
In terms of geographic, North America and Europe dominates the global bio-engineered protein drugs market due to improved biopharmaceutical industry in the region. The U.S. represents the largest market for bio-engineered protein drugs followed by Canada in North America. In Europe, France and Germany holds major share of bio-engineered protein drugs market. However, Asia is expected to show high growth rates in the next five years in global bio-engineered protein drugs market due to improving life science research infrastructure in the region. Japan, China and India are expected to be the fastest growing bio-engineered protein drugs market in Asia.
Click Here for more information..